Kedrion Biopharma announces that Congenital Plasminogen Deficiency patients in the US now have access to RYPLAZIM®, the first FDA-approved treatment for the approximately 500 people in the US affected by this disease. This is an ultra-rare disease that leads to reduced Plasminogen activity levels in the body, often resulting in fibrinous lesions on various organs. About 81% of the patients develop lesions on one or both eyes as their lead symptom, but lesions can develop throughout the body on all organs with mucous membranes. Patients affected by this disease may require lifelong treatment.
“This therapy brings hope and relief to patients of all ages who have long awaited effective treatment options for this disease,” said Bob Rossilli, Chief Commercial Officer, Global Business of Kedrion Biopharma. “We are expediting production and distribution to US patients and are proud to provide adult and pediatric patients with this treatment””
It is the latest example of the company’s commitment to expanding access to life-changing drugs to rare disease patients globally.
